BioSpace News Archive

Mood disorder, also known as affective disorder, is a mental health issue characterized by a serious change in mood that affects the person’s daily life

Guardant Health, Inc., a leading precision oncology company, and Vall d’Hebron Institute of Oncology, one of Europe’s leading cancer research organizations, have agreed to enter into a partnership to establish in-house liquid biopsy testing services, using Guardant Health’s industry-leading proprietary digital sequencing platform, at VHIO’s facility in Barcelona, Spain.

EdiGene, Inc., announced the Center for Drug Evaluation of China National Medical Products Administration has approved the Company’s Investigational New Drug application for ET-01, an investigational CRISPR/Cas 9 gene-editing therapy for patients with transfusion dependent β-thalassemia.

The treatment could be administered in primary care centers to people who test positive for COVID-19, avoiding hospitalization due to the progression of the disease and complementing the vaccine in the early phase after vaccination

Today Syntegra and the National Institutes of Health (NIH) have announced a collaboration to validate Syntegra’s AI-enabled synthetic data technology to advance the understanding of and care for COVID-19. Using Sy

Valeo Pharma Inc. (CSE: VPH) (OTCQB: VPHIF) (FSE: VP2) (“Valeo” or the “Company”), a Canadian pharmaceutical company, announced today the appointment of Mr. Frederic Fasano to the newly created position of President and Chief Operating Officer, effective January 18th, to augment its senior leadership team and support expansion of Valeo’s commercial activities.

AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo)’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.

Resverlogix Corp. (“Resverlogix”, or the “Corporation”) (TSX:RVX) today announced that on January 28th, 2021 at 10:00 am MT, it will be hosting a webcast and conference call for the purpose of updating stakeholders regarding three key areas

NexImmune today announced the appointment of Dr. Robert (Bob) Knight as Chief Medical Officer (CMO). Dr. Knight is a seasoned executive with extensive experience leading early- and late-stage immunotherapy product development teams

Propanc Biopharma, Inc. (OTC: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the Company has received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors in pancreatic and ovarian cancers.